Microbot Medical

Company Overview

Snapshot

Founded in November 2010 by Harel Gadot, Microbot Medical operates with 11–50 employees. The company has raised a total of $90.52 million across 15 funding rounds from 2 investors. In September 2025, the company received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System.

Business overview

Microbot Medical specializes in transformational robotic technologies, primarily focusing on the endovascular space. Its core product, the LIBERTY Robotic System, is designed as the world’s first single-use endovascular robotic system, aiming to increase access to robotic technology and revolutionize endovascular procedures. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving the healthcare industry and providers with solutions in robotics, endoscopy, and minimally-invasive procedures.

Strategic signal

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System. This regulatory approval is a significant validation of the company's technology and signals a critical step towards commercialization, enhancing its market position and potential for widespread adoption in endovascular procedures.

Company Intelligence Q&A

What was a key regulatory achievement for Microbot Medical in 2025?

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, enabling its commercialization in the US market.

What significant funding event occurred for Microbot Medical in October 2025?

In October 2025, Microbot Medical announced the final closing of the exercise of outstanding preferred investment options, generating up to $92.2 million in gross proceeds.

What was a notable strategic partnership announced by Microbot Medical in November 2025?

In November 2025, Microbot Medical announced that Emory University Hospital became the first hospital globally to adopt the new LIBERTY Endovascular Robotic System, marking a significant step in the system's market penetration.

What was the outcome of Microbot Medical's pivotal human clinical trial in October 2024?

In October 2024, Microbot Medical announced the successful completion of its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System, accelerating its go-to-market strategy for a commercial launch in Q2 2025.

When did Microbot Medical acquire a novel technology from CardioSert?

In May 2018, Microbot Medical closed the acquisition of a novel, patent-protected technology from CardioSert, including all research and development information, technical know-how, and intellectual property.